comprehensive -WSS

comprehensive

author：hotspot 2025-10-03 01:04:34 - browse：268

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： A new study asks: Are we harming blood donors by taking blood?

hotspot

WSS

Drastic changes should bring profitability, startup health insurers say

In same hospitals, Black patients receive fewer opioids than white patients

In same hospitals, Black patients receive fewer opioids than white patients

American woman, child freed after being kidnapped in Haiti last month

For Cytokinetics, FDA rejection of heart drug would help, not hinder

These geoengineering technologies could help combat the climate crisis, scientists say

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Walensky prepares to leave CDC — and Congress — behind

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Affirmative action in medical school literally saved lives

Naloxone nonprofit donates 200,000 doses after FDA approval

Moonlake's readout produced a cash windfall. Risks remain

4th of July breaks record for highest global temperature ever measured

Dobbs anniversary: the lost opportunity of abortion as health care

7 people shot in DC, police say

Dobbs anniversary: the lost opportunity of abortion as health care

The best solution to the drug shortages problem

Wikipedia

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

How to use technology to prevent future drug shortages

Bacterial infection may be ‘key event’ in endometriosis, study says

Wegovy’s successful heart trial raises vital question about weight loss

Why is France rioting? What to know about the fatal police shooting of Nahel M

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Wikipedia

hotspot

hotspot

leisure time